TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind
(Part B), and open-label multiple dose extension (Part C) study will be conducted in male and
female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in
improving symptoms of orthostatic intolerance.
Phase:
Phase 2
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma R & D, Inc.